This retrospective analysis of data from 3 randomized clinical trials examines the association of pathologic complete response with event-free survival by intrinsic subtype and other gene expression signatures in patients with ERBB2/HER2-positive early breast cancer treated in the neoadjuvant setting. The gene discussed is ERBB2; the disease is breast cancer.